Emerging Trends in the Incidence (1999–2022) and Mortality (1999–2023) of Thyroid Cancer in the United States: CDC WONDER Database Study
Endocrinology and Metabolism · 31.10.2026 · 41 (5) · 659-670
DOI: 10.3803/enm.2025.2810 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology and Metabolism, erschienen am 31.10.2026. Verfasst von Fanrui Meng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biolog…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Mortality. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Clinical Key Specialty Construction Program.
Abstract (Originalsprache)
Background
Thyroid cancer (TC) is a common endocrine malignancy with a rising global incidence. This study examined trends in TC incidence and mortality in the United States over the past two decades.
Methods
TC mortality data from 1999–2023 and incidence data from 1999–2022 were obtained from Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research. Age-adjusted incidence rates (AAIRs) and age-adjusted mortality rates (AAMRs) per 100,000 person-years were standardized to the 2000 United States standard population. Temporal trends were analyzed using the Joinpoint Regression Program to calculate annual percent changes (APCs) and average annual percent changes (AAPCs) with 95% confidence intervals. Analyses were stratified by sex, age, race, and census region. A sensitivity analysis restricted to 1999–2019 was also conducted.
Results
Overall, 933,521 TC cases and 43,071 TC-related deaths were identified, with an AAIR of 12.12 and an AAMR of 0.49. Incidence rose markedly from 1999 to 2009 (APC=7.25%), stabilized during 2009–2014, and declined from 2014 to 2022 (APC=−2.42%), especially among females. In males, incidence increased until 2011 and then declined slightly. Mortality increased modestly overall (AAPC=0.30%), mainly among males and adults aged ≥75 years. The Northeast had the highest AAIR (15.73), whereas the West had the highest AAMR (0.55). Non-Hispanic Whites had increasing mortality, while non-Hispanic Blacks had the lowest incidence.
Conclusion
In the United States, TC incidence shifted from increase to decline, coinciding with growing awareness of potential overdiagnosis. In contrast, mortality continued to show a modest upward trend, underscoring the importance of ongoing surveillance and focused attention to high-risk populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, State Key Laboratory of Female Fertility Promotion, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing,…
- Department of General Surgery, Peking University Third Hospital, Beijing, China.
Förderung
- National Natural Science Foundation of China
- National Clinical Key Specialty Construction Program
Zitieren
APA
Meng, F., Gao, Y., Li, X., & Liu, A. (2026). Emerging Trends in the Incidence (1999–2022) and Mortality (1999–2023) of Thyroid Cancer in the United States: CDC WONDER Database Study. Endocrinology and Metabolism, 41(5), 659-670. https://doi.org/10.3803/enm.2025.2810
Vancouver
Meng F, Gao Y, Li X, Liu A. Emerging Trends in the Incidence (1999–2022) and Mortality (1999–2023) of Thyroid Cancer in the United States: CDC WONDER Database Study. Endocrinology and Metabolism. 2026;41(5):659-670. doi:10.3803/enm.2025.2810
BibTeX
@article{Meng2026,
author = {Meng, Fanrui and Gao, Yixin and Li, Xin and Liu, Aihua},
title = {Emerging Trends in the Incidence (1999–2022) and Mortality (1999–2023) of Thyroid Cancer in the United States: CDC WONDER Database Study},
journal = {Endocrinology and Metabolism},
year = {2026},
volume = {41},
number = {5},
pages = {659--670},
doi = {10.3803/enm.2025.2810}
}
EUVIMED